Xinglinxing Investment Management

Xinglinxing operates as a healthcare-specialist private equity firm, deploying across seed, start-up, expansion, late-stage, and pre-IPO rounds. A dedicated fund-of-funds sleeve complements the direct investment activity, allocating capital to external healthcare-focused managers. The firm does not invest outside the healthcare and life sciences sectors.

The firm runs both a direct investment arm and a fund-of-funds program, both dedicated to healthcare. This hybrid structure is unusual among China's domestic PE platforms, where most firms operate purely direct strategies. It allows Xinglinxing to evaluate external managers while maintaining proprietary sourcing capabilities.

Xinglinxing is headquartered in Nanjing, within Jiangsu province — a dense biotech corridor that generates significant deal flow locally. The firm also evaluates opportunities across other Chinese healthcare innovation hubs, including Shanghai and Suzhou, drawing on domestic scientific networks. Its fund-of-funds relationships provide additional deal access through external manager channels.

Xinglinxing covers the full healthcare investment lifecycle, from early-stage seed and start-up rounds through expansion and late-stage growth, including pre-IPO placements. The fund-of-funds sleeve allows allocation to managers with complementary stage focus, broadening the firm's effective coverage without direct mandate drift.

No. Xinglinxing has not publicly disclosed AUM figures or team size, consistent with a private China-based fund manager that does not report to foreign limited partners. Performance data and portfolio company names likewise remain unpublished.